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Abstract
Aim: The aim of this study is to evaluate the acute effects of sacral
neuromodulation (SNM) on various urodynamic parameters.
Methods: Patients with overactive bladder and detrusor overactivity (DO) who
were planned for percutaneous nerve evaluation (PNE) were included. Directly
after the PNE, a urodynamic study (UDS) was performed. The stimulation was
turned off during the first UDS (UDS 1), and during the second filling cycle,
stimulation was turned on (UDS 2). The UDS was followed by a test phase of 1
week and the bladder diaries were evaluated during an outpatient clinic visit.
Primary outcome measures were the differences in UDS parameter values with
SNM off and on.
Results: Ten female patients were included in the study and completed the
study protocol. Eight patients showed ≥50% improvement of symptoms
following a test phase. There were no differences between UDS 1 and UDS 2
in the UDS parameters; bladder volume at first sensation, bladder volume at
first DO, highest DO pressure, bladder capacity, maximum flow rate, and
pressure at maximum flow rate.
Discussion: None of the aforementioned urodynamic parameters was
influenced by acute SNM in patients who responded to SNM. To the best of
our knowledge, this is the first study investigating the acute effects of SNM on
bladder function.
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1 | INTRODUCTION
Overactive bladder (OAB) is a condition defined as
urgency, with or without urgency urinary incontinence,
usually associated with frequency and nocturia.1 The
prevalence is described to be between 11% and 16%
worldwide and is expected to increase as a result of the
aging of the population causing a high burden on
society.2,3 The pathophysiology of this highly prevalent
disease is still being explored and the value of urody-
namics (UDS) in OAB is investigated. About 54.2% of
patients with symptoms of OAB show detrusor over-
activity (DO) on UDS.4
Currently, first‐line treatment consists of conservative
treatments like pelvic floor muscle therapy (PFMT)
and second‐line treatment of oral anticholinergics or
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betamimetics. Neither of these treatments is very
efficient. Research shows that the benefit of PFMT is
not maintained on the long term and more than 50% stop
anticholinergic drug treatment within the first 3 months
because of lack of benefit and adverse effects.5
Sacral neuromodulation (SNM) is a safe and effective
third‐line therapy for symptoms of OAB.6 SNM is supposed
to suppress involuntary bladder contractions and to normal-
ize bladder sensation via afferent nerve modulation.7 Before
implantation of a sacral neuromodulator, a percutaneous
nerve evaluation (PNE) or first‐stage tined lead placement
test (FSTLP) is done to evaluate the efficacy in the patients
with OAB. In patients with an improvement of ≥50% of
symptoms, evaluated with bladder diaries, a sacral neuro-
modulator is implanted.5
Different properties of SNM in bladder dysfunction have
been investigated, such as the onset of action, the wash‐out
period, and the effectiveness of intermittent and on‐demand
SNM.8-11 An argument for intermittent or on‐demand SNM
was a longer battery life, and, consequently, fewer surgical
replacements, although the need for intermittent SNM is less
urgent since the introduction of the rechargeable battery.12 In
some studies, it was found that the efficacy of SNM
decreased after 5 years.13 Adaption by the nervous system
was postulated as the cause of this.10,14 Other studies found
that the therapeutic effect of SNM was stable after 5 to
6 years.6,15
Implantable ultrasound devices and potentiometers to
detect bladder filling and contractions have been studied in
pigs.16,17 Such devices could be helpful in the development of
a feedback system in which the neuromodulator automati-
cally activates when the detrusor pressure is increasing.18 If
acute SNM has direct inhibitory effects on bladder function,
such a closed‐loop feedback system could be of potential
value for patients with OAB. Studies in rats demonstrated an
acute inhibitory effect of neuromodulation on bladder
contractions.19
Whether UDS parameters can predict the success of
SNM in patients have been investigated, but no predictive
UDS parameters have been found.20,21 Moreover, when
comparing UDS parameters before and during SNM (6
months stimulation), several UDS parameters signifi-
cantly changed; bladder volume at first sensation, bladder
capacity, maximum detrusor pressure, and maximum
flow rate (Qmax).22-24 The acute effect of SNM on UDS
has never been investigated.
Therefore, the aim of this study is to evaluate the
acute effect of SNM on the different UDS parameters.
2 | MATERIALS AND METHODS
The present study was approved by the local medical
research ethics committee (METC 2017‐471). Before the
study, written informed consent was obtained from all
patients. Participation in this study was voluntary with
no explicit incentives provided for participation.
2.1 | Patients
Patients with OAB and urodynamically proven DO, who
were scheduled for PNE, were eligible for screening.
Exclusion criteria were age under 18 years, intravesical
botulinumtoxinA injections in the past 9 months, predomi-
nant stress urinary incontinence, bladder pain syndrome,
neurogenic bladder, urinary tract infection, having an
indwelling catheter, previous radiotherapy of the pelvis,
pregnancy, and malignancies of the lower urinary tract.
2.2 | Intervention
Our standard care procedure for PNE was performed and
is as follows. All anticholinergics and β3‐adrenoceptor
agonists were stopped 2 weeks before the PNE. The PNE
is done in the outpatient clinic under local anesthesia.
PNE’s were performed using the PNE sets of Medtronic
(four patients) or Axonics (six patients). A test electrode
is inserted into one of the S3 foramens of the sacrum.
Placement is considered correct if stimulation is felt in
the vagina, penis, perineum, or anus. The electrode is
then connected to the external nerve stimulator (ENS). In
the current study, the patient underwent a urodynamic
study (UDS 1) after placing the electrode but before the
ENS was turned on. This urodynamic study was
performed according to the International Continence
Society criteria, using a 7‐Fr transurethral double‐lumen
catheter and an 8‐Fr rectal pressure sensor.25,26 The
bladder filling rate was 50mL/min. The patient was
asked to indicate the first sensation of bladder filling, the
first desire to void, and the moment of a strong desire to
void. Permission to void was then given. Postvoid
residual volume was determined through the catheter.
Next, the ENS was turned on with the stimulation
amplitude just above the sensory threshold and the pulse
width and frequency set at 210 µs and 14 Hz, respectively.
The UDS was then repeated (UDS 2). The patients were
given antibiotics for 3 days to prevent urinary tract
infections following the UDS. After the UDS, the
standard procedure was resumed, that is, the patient
completed a bladder diary, which was evaluated after 1
week. The PNE was considered positive if at least 50%
improvement was obtained in at least one of the
symptoms (frequency, voided volume, or incontinence
episodes). In case the PNE was inconclusive, an FSTLP
was proposed in which the permanent lead is placed in
one of the S3 or S4 foramens and is connected to an
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external stimulator. Stimulation parameters were the
same as during PNE. This test phase has a duration of
about 1 month and the evaluation of success is done on
the basis of bladder diary results of at least 3 days, which
is comparable to the PNE evaluation.
2.3 | Outcome measures
Demographic data, data from bladder diaries and the results
of the PNE and FSTLP, were extracted from the medical
record (Table 1). The outcome measures were various UDS
parameters as given in Table 2. The results of three different
UDS were compared: UDS B (performed at baseline, before
the PNE, as a part of our standard procedure of care), UDS 1
(after the PNE, without stimulation), and UDS 2 (after the
PNE, with stimulation). During UDS B two filling voiding
cycles were performed. Of these two cycles, the data of the
filling phase with the highest filled volume and the data of
the voiding phase with the highest Qmax were used in the
current study.
2.4 | Statistical analysis
All statistical analyses were done with the Wilcoxon
signed‐rank test for nonparametric‐related samples,
using SPSS version 24.0 (IBM Corp, Armonk, NY).
3 | RESULTS
A total of 10 female patients with a mean age of 59
(interquartile range 54‐63) years were willing to partici-
pate and completed the study protocol, see Table 1 for
patient characteristics. All patients had OAB for at least 2
years with proven DO on UDS B. All patients except for
one (patient 9) also showed DO during UDS 1 and UDS 2.
The PNE was positive in four patients, inconclusive in
four patients, and negative in two patients (patients 2 and
9). The four patients with an inconclusive result reported
to feel stimulation during UDS 2 but lost sensation after 2
to 4 days, possibly due to the displacement of the lead. An
FSTLP was next done, with a positive outcome in all four
patients. Consequently, a permanent neuromodulator
was implanted in eight patients.
The median UDS 1 and UDS 2 parameters of the
positively responding eight patients are shown in Table 2.
No statistically significant differences were found be-
tween UDS parameters without stimulation (UDS 1) and
with stimulation (UDS 2). Figure 1 shows UDS para-
meters during the filling phase, three data points are
shown; UDS at baseline, UDS directly after the PNE
without stimulation (UDS 1), and UDS directly after PNE
with stimulation (UDS 2). The lines represent the eight
positively responding individuals and their median. In
the outcome parameter “bladder volume at first sensa-
tion,” four lines are missing. These patients did not
indicate when the first sensation was notified. UDSTABLE 1 Patient characteristics
N
Male/female 0/10
Age during PNE, y, median (IQR) 59 (54‐63)
Frequency/24 h, median (IQR) 13 (11‐15)
Nocturia episodes, median (IQR) 4 (2‐6)
Incontinence episodes, median (IQR) 3 (1‐5)
Pad use/24 h, median (IQR) 3.5 (1‐5)
Functional bladder capacity, mL, median (IQR)a 246 (125‐400)
Overactive bladder
Wet 9
Dry 1
Concomitant bladder problems
Mixed incontinence 3
Therapies before PNE
Pelvic floor muscle therapya 4
Anticholinergics 10
TENS/PTNSa 4
OnabotulinumtoxinAa 3
Abbreviations: IQR, interquartile range; PNE, percutaneous nerve evalua-
tion; PTNS, percutaneous tibial nerve stimulation; TENS, transcutaneous
electrical nerve stimulation.
aData of one patient was incomplete.
TABLE 2 Urodynamic parameters of UDS 1 and UDS 2
UDS 1 UDS 2 P value*
Filling phase
Bladder volume at first
sensation
157mL 115mL .854
IQR (89‐290) (63‐147)
Bladder volume at first DO 184mL 179mL .263
IQR (110‐300) (125‐340)
Highest DO pressure 32 cmH2O 32 cmH2O .574
IQR (21‐35) (21‐35)
Bladder capacity, mL 175mL 190mL .401
IQR (79‐518) (160‐364)
Micturition phase
Maximum flow rate 12 mL/s 10mL/s .462
IQR (10‐17) (6‐14)
Pressure at maximum flow 31 cmH2O 31 cmH2O .089
IQR (26‐43) (27‐39)
Abbreviations: DO, detrusor overactivity; IQR, interquartile range; UDS,
urodynamic study.
*Wilcoxon signed‐rank test for nonparametric‐related samples.
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parameters of the voiding phase are shown in Figure 2.
Qmax and the pressure at maximum flow rate did not
change significantly comparing UDS 1 and UDS 2, also
shown in Table 2.
4 | DISCUSSION
To the best of our knowledge, this is the first study that
suggests that SNM has no significant acute effect on
standard UDS parameters in patients with OAB in whom
SNM is eventually an effective treatment. This accounts
for both the filling phase and the voiding phase. The
figures show that besides the median change of the
parameters, the individual changes are also limited.
These results are complementary to the results of
previous studies. Significant changes in UDS parameters
were demonstrated after 6 months of SNM in patients
with DO for both the filling and the voiding phase; the
bladder volume at first sensation increased, the bladder
FIGURE 1 Urodynamic parameters of the filling phase of UDS B, UDS 1, and UDS 2. DO, detrusor overactivity; UDS, urodynamic
study
FIGURE 2 Urodynamic parameters of the voiding phase of UDS B, UDS 1, and UDS 2. UDS, urodynamic study
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capacity increased, the maximum detrusor pressure
during the filling phase decreased, and the Qmax
increased.22-24
The working mechanism of SNM is still being
investigated, but at present, it is believed that SNM
activates afferent pathways modulating several brain
areas which, in turn, regulate bladder control. Differ-
ences between acute and chronic SNM in regional
cerebral blood flow (rCBF) have been demonstrated
using PET.7 When acute SNM is applied, brain areas
predominantly involved in sensorimotor control, showed
an increase in rCBF. Moreover, during acute SNM, Blok
et al described a change of rCBF in the insula. Blok et al7
argued that this might cause the activation of the
sympathetic system, which, in turn, results in an increase
in the bladder capacity. The bladder capacity was not
measured during this PET study. The current study did
not demonstrate an increase in the bladder capacity after
acute SNM. In contrast to us, the study of Opisso et al did
show such an increase. They used subject‐controlled
dorsal genital nerve stimulation in patients with neuro-
genic bladders due to partial spinal cord injury, multiple
sclerosis, or traumatic brain injury.27 Subjects could turn
on the stimulator as soon as they felt urgency during
bladder filling. However, the underlying mechanisms of
bladder dysfunction in neurogenic and idiopathic pa-
tients are not comparable.28 In the present study, only
patients with idiopathic OAB were included. During
chronic stimulation, when SNM has been active for 6
months, changes in the rCBF in brain areas involved in
attention and alertness were detected.7 This, in turn,
would result in less firing of the pontine micturition
center and restore bladder function. The fact that this
rCBF change in the brain areas involved in attention and
alertness is only detected after chronic SNM and not after
acute SNM might be related to the working mechanism
of SNM and could explain the differences in results in
UDS between acute and chronic stimulations. The areas
predominantly involved in sensorimotor control showed
a decrease in rCBF after chronic stimulation, instead of
the increase in rCBF after acute SNM. This change might
also explain the differences in results in UDS between
acute and chronic stimulations.The wash‐out duration of
SNM has been investigated. Cadish et al8 found a mean of
11.25 days before the return of symptoms after turning
the SNM off in 12 women with OAB. Altomare et al9
detected that in 19 patients with urinary incontinence or
fecal incontinence, the mean time to the recurrence of
symptoms after turning the SNM off was 3.4 months
(range 0.9‐13.5) and in nine patients symptoms never
returned. In conclusion, chronic effects of SNM seem to
be maintained some time after stimulation is stopped,
suggesting neuroplasticity of the involved brain areas.
Moreover, the onset of action of SNM was recently
investigated using bladder diaries which indicated that
the mean time to 50% or greater symptom improvement
was 3.3 days.29
These results, and those of the current study, suggest
that a closed‐loop feedback system, which activates SNM
automatically when the detrusor pressure increases,
would not be effective due to lack of acute effects after
such short stimulation. However, on‐demand and inter-
mittent neuromodulations have been proved to be
effective therapies in two separate trials.11,14 A possible
explanation might be that in both trials, the patients were
already using the SNM for more than 7 years and 48
months, respectively.11,14 The aforementioned neuroplas-
ticity of the involved brain areas might already have been
utilized, indicating that hypothetically, these neuroplastic
changes can be maintained by intermittent or on‐demand
neuromodulation. Suggestions for future research in the
use of a feedback neuromodulation system would be to
investigate it with patients who are long‐term users and
who are starting users of SNM.
The main limitation of the current study is its small
sample size. We initially aimed at larger sample size.
However, considering the absence of statistically sig-
nificant findings in eight successfully tested patients and
the invasiveness of the UDS, we decided to stop inclusion
for ethical reasons. In four patients, the first sensation of
bladder filling was not noted because they had an
involuntary detrusor contraction followed by direct urine
leakage and micturition. Four patients had undergone an
FSTLP after the PNE because of inconclusive PNE
results. This inconclusive PNE was most likely caused
by lead migration as all four patients described a loss of
sensation of stimulation of stimulation after some days.
Lead migration is a known disadvantage of PNE
compared with an FSTLP and might be the cause that
PNE is a less sensitive screening method than FSTLP.30
In our hospital, patients with OAB first undergo a PNE,
in case this is inconclusive, an FSTLP is conducted. The
influence of this on our study results is considered
minimal, since all four patients reported to feel stimula-
tion during the UDS 2 at the same location as during the
placement of the PNE lead. Moreover, the stimulation
parameters used during PNE and FSTLP were the same
(frequency 14 Hz and pulse width 210 μs). Ultimately, for
this study, it was merely of relevance whether or not the
patient is a responder to SNM in general. The method of
testing is of secondary importance.
In conclusion, this study suggests that there are no
acute effects of SNM on conventional UDS parameters.
More studies are needed to confirm this finding and
further elucidate the role of factors, such as sex, age, and
etiology of OAB.
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